InDevr Planning 2016 Launch for FluChip-8G, Aims to Make Test 'Standard of Care' for Flu Dx | GenomeWeb

NEW YORK (GenomeWeb) – By the end of 2016, InDevr aims to have a microarray-based clinical test on the market for genotyping influenza viruses.

The Boulder, Colo.-based company recently received a federal contract worth up to $14.7 million to develop the assay, called FluChip-8G, with the goal of supporting the test through US Food and Drug Administration clearance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.